Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-1284 in Agitation Associated With Alzheimer's Dementia
NCT06651567Phase 2Recruiting
- Sponsor
- Intra-Cellular Therapies
- Start
- Oct 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in agitation comparing ITI-1284 with Placebo (2 arms). Primary endpoint: Cohen-Mansfield Agitation Inventory at 12 weeks. Started Oct 2024; status: recruiting.
02
Drugs
deulumateperone
03
Conditions
agitation
Beyond the preview
Go deeper on NCT06651567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06651567.